– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War –

KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder ("PTSD") using brain scans collected on its FDA-510(k)-cleared Evoke System.

The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War ("DoW") to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury ("TBI"). The identification of a novel PTSD-specific electrophysiological biomarker deepens the scientific foundation of that DoW deployment and positions Firefly as what it believes to be the only company with both an active government brain health partnership and a identified neural signal marker for the condition.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.